












12NatOptimization of Therapy for Severe Aplastic Anemia
Based on Clinical, Biologic, and Treatment Response
Parameters: Conclusions of an International Working
Group on Severe Aplastic Anemia Convened by the
Blood and Marrow Transplant Clinical Trials
Network, March 2010
Michael A. Pulsipher,1 Neal S. Young,2 Jakub Tolar,3
Antonio M. Risitano,4 H. Joachim Deeg,5 Paolo Anderlini,6 Rodrigo Calado,2 Seiji Kojima,7
Mary Eapen,8 Richard Harris,9 Phillip Scheinberg,2 Sharon Savage,10
Jaroslaw P. Maciejewski,11 Ramon V. Tiu,11 Nancy DiFronzo,12
Mary M. Horowitz,8 Joseph H. Antin13Although recent advances in therapy offer the promise for improving survival in patients with severe aplastic
anemia (SAA), the small size of the patient population, lack of a mechanism in North America for longitudinal
follow-up of patients, and inadequate cooperation among hematologists, scientists, and transplant physicians
remain obstacles to conducting large studies that would advance the field. To address this issue, the Blood
and Marrow Transplant Clinical Trials Network (BMT CTN) convened a group of international experts in
March 2010 to define the most important questions in the basic science, immunosuppressive therapy
(IST), and bonemarrow transplantation (BMT) of SAA and propose initiatives to facilitate clinical and biologic
research. Key conclusions of the working group were: (1) new patients should obtain accurate, expert diag-
nosis and early identification of biologic risk; (2) a population-based SAA outcomes registry should be estab-
lished in North America to collect data on patients longitudinally from diagnosis through and after treatment;
(3) a repository of biologic samples linked to the clinical data in the outcomes registry should be developed;
(4) innovative approaches to unrelated donor BMT that decrease graft-versus-host disease are needed; and
(5) alternative donor transplantation approaches for patients lacking HLA-matched unrelated donors must
be improved. A partnership of BMT, IST, and basic science researchers will develop initiatives and partner
with advocacy and funding organizations to address these challenges. Collaboration with similar study groups
in Europe and Asia will be pursued.
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Aplastic anemia is a marrow failure syndrome with
an incidence of 2 per million inWestern countries and
4-6 per million in Asia [1,2]. In the vast majority of
patients, the disease results fromTcell–mediated auto-
immune destruction of marrow elements leading to
life-threatening cytopenias. The preferred therapy for
younger patients with severe aplastic anemia (SAA) is
HLA-matched sibling allogeneic bone marrow trans-
plantation (BMT), which results in long-term survival
in 85% to 90% of recipients [3-5]. Only 20% to 30%
of patients will have HLA-matched siblings, and
some will not receive an upfront BMT approach
because of patient choice, physician preference, or
BMT access issues. Hence, most patients with SAA
receive initial treatmentwith immunosuppressive ther-
apy (IST), most commonly with a combination of an-
tithymocyte globulin (ATG) and cyclosporine (CsA).
Although 60% to 75% of patients respond with a de-
crease in or elimination of transfusion requirements,
10% to 35% of patients will relapse (require transfu-
sions again), and the majority of patients will require
long-term (5-year) therapy with CsA [6,7]. Others are
at risk of clonal evolution to hemolytic paroxysmal
nocturnal hemoglobinuria (PNH), myelodysplasia
(MDS), or acute myeloid leukemia (AML) [8,9].
Well-matched unrelated donor (URD) BMT can
be successful in patients failing immunosuppression,
but because transplant-related mortality (TRM) and
graft-versus-host disease (GVHD) are higher than
with HLA-matched sibling BMT, there has been lim-
ited enthusiasm for this approach in the past.Figure 1. Treatment of acquired severe aplastic anemia according to United Ki
FBC, full blood count (or CBC); MUD, matched unrelated donor; CRP, clinical
blood.With recent improvements in survival after URD
BMT [10-12] SAA experts from the United Kingdom
published guidelines recommending matched URD
BMT if patients fail to respond to IST after 4-6
months (Figure 1) [13]. This approach is being adopted
more widely in Europe and Japan, supported by a pro-
spective study in Japanese pediatric patients [14]. Pro-
spective validation of these guidelines in older adults is
needed, and several key questions about URD trans-
plantation in SAA remain: (1) It is not clear when to of-
fer URD transplantation to patients who relapse after
an initial response to IST, asmost patients will respond
to further treatment with IST. (2) Half of SAA patients
will not have a well-matched URD, and the role of al-
ternative donor procedures such as unrelated cord
blood (UCB) or haploidentical related donor trans-
plantation is unclear. (3) Finally, there are inadequate
data regarding long-term quality of life after URD
BMT for SAA. If survival is improved after transplant,
does it come at a high cost?
Answering these questions is challenging, as it
requires comprehensive tracking of patients from diag-
nosis through all therapies. Long-term follow up of
SAA patients is especially important because many ad-
verse events (MDS/AML) can occur 1-2 decades after
diagnosis. In the United States, except in a few centers,
long-term outcomes of patients with this rare disorder
are not followed. The Center for Blood and Marrow
Transplant Research (CIBMTR) collects long-term
outcome data on the minority of patients who undergo
BMT, but data collected regarding therapies prior
to transplantation is often inadequate to address
many issues. More importantly, there is no effectivengdomGuidelines [13]. ATG, antithymocyte globulin; CSA, cyclosporine;
research protocol; IST, immunosuppressive therapy; UCB, umbilical cord
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with comparable patients receiving IST approaches.
In view of these challenges, an ad hoc SAA Com-
mittee was formed by the Steering Committee of the
Blood and Marrow Transplant Clinical Trials Net-
work (BMT CTN), a program sponsored by the
National Heart, Lung, and Blood Institute and the
National Cancer Institute, to consider potential re-
search strategies in this disease. The Committee con-
vened a working group of international experts in
March 2010 in Bethesda, Maryland, in conjunction
with an educational and scientific meeting sponsored
by the Aplastic Anemia andMyelodysplastic Syndrome
International Foundation. The purpose of the working
group was to: (1) define the most pressing questions in
the basic science and therapy of SAA that could be ad-
dressed through clinical trials; (2) establish an approach
to identify biologic and clinical parameters of SAA that
define risk, both with IST and BMT; and (3) initiate
a process that will result in the identification of rational
intervention points, where URD and alternative donor
BMT approaches can be compared with IST.
The conclusions of this working group are summa-
rized below.Figure 2. Probability of survival in patients treated with ISTwho had
high versus low absolute reticulocyte counts (ARC) and high versus
low absolute lymphocyte counts (ALC). Patients undergoing BMT
were censored at the time of transplant [27].New Insights into SAA Biology, Key Issues
for Study
Idiopathic SAA patients have immune-mediated
oligoclonal expansion of cytotoxic T cells targeting he-
matopoietic stem and progenitor cells. These T cells
have a Th1 profile and secrete interferon-g [15]; po-
tentially relevant polymorphisms in genes associated
with an increased immune response have been identi-
fied [16]. Regulatory T cells (T-regs) are decreased
in almost all patients with SAA [17], and infusion of
T-regs abrogates lymphocyte-inducedmarrow dyspla-
sia in mouse models [18].
A notable observation in a portion of patients with
SAA is the presence of shortened telomeres [19,20].
Mutations of the telomerase enzyme complex (TERT,
TERC, DKC1, NOP10, or NHP2) or in the shelterin
telomere protection complex (TINF2) form the basis
for the inherited marrow failure disorder dyskeratosis
congenita. Just under 10% of SAA patients will have
a mutation in either TERT or TERC. A smaller
percentage of patients with SAA and no other clinical
phenotype will have a mutation in TINF2. Genetic
variants in TERF1 may also contribute to risk of SAA,
although to a lesser extent [21]. All of these genes are
thought to contribute to telomere erosion, increasing
risk of marrow failure and malignant transformation.
Although telomere length does not predict response to
immunosuppression in SAA patients (as opposed to dys-
keratosis congenitapatientswhodonot respond to IST),
retrospective studies show that SAA patients with
shorter telomeres at diagnosis are at higher risk ofrelapse after IST and are also more likely to undergo
clonal evolution to MDS or AML [22].
The impact of telomere dysfunction on BMT out-
comes in SAA is not known. Patients with dyskeratosis
congenita have a high incidence of organ toxicity, most
notably hepatic and pulmonary, after BMT [23-25]. In
telomerase knockout mice (Terc2/2), short and dys-
functional telomeres preclude appropriate engraft-
ment of donor wild-type hematopoietic stem cells,
possibly because of poor stromal function [26]. A large
study correlating telomere length with engraftment,
toxicity, and survival in patients who received unre-
lated donor BMT for SAA over the past decade is cur-
rently underway through the National Marrow Donor
Program (NMDP) and CIBMTR. Although this study
may define putative risks associated with shorter telo-
meres during URD BMT, prospective studies will be
needed to test the applicability of these associations
with modern BMT therapy.
Until recently, laboratory-based predictive bio-
markers for IST response in SAAwere lacking. Schein-
berg [27] and the NIH group correlated absolute
reticulocyte count (ARC) and absolute lymphocyte
count (ALC) at initial diagnosis with response, identi-
fying groups at low and higher risk of failure and early
mortality (Figure 2). Further investigation showed that
ARC combined with telomere length had better pre-
dictive power than either biomarker alone. Patients
with both high ARC and longer telomeres appear to
have excellent outcomes, whereas those with low
ARC and shorter telomeres do poorly; patients with
only 1 of the 2 adverse factors had intermediate out-
comes [28]. Important follow-up questions to address
include: (1) does the prognostic ability of these assays
hold up in a prospective multicenter cohort; and (2)
can intervention with URD BMT improve survival
of patients with low ARC and shorter telomeres com-
pared to IST? Other important goals for future trials
are discovery of additional biologic factors with
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gle nucleotide polymorphism [SNP-A] genotypes,
etc.), or identification of genetic aberrations that con-
tribute to the pathophysiology of SAA.Advances in Immunosuppression and
Supportive Care: Next Steps
Initial therapy of SAA with horse ATG and CsA,
standard for more than 2 decades, results in response
rates of 50% at 3 months and 60% to 75% at 6 months
[29-31]. A second course of rabbit ATG given after
a minimum of 3 months may lead to response in
about a third of patients who do not respond to the
first course [32]. Among patients who respond initially
but later relapse, most will have some response to
subsequent courses of immunosuppressive therapy.
Slowing the rate of taper of CsA appears to decrease
the likelihood or delay the onset of relapse [33].
Over the past decade, researchers sought to in-
crease initial response rates by increasing the intensity
of IST through the addition of mycophenolate mofetil
(MMF), sirolimus, or other agents to ATG/CsA
[34,35]. These efforts were not successful, suggesting
that even intense IST is insufficient to abrogate the
autoimmune aggression in somepatients, or that someof
patients have more severe destruction of hematopoietic
progenitors resulting in worse marrow reserve and
insufficient stem cells to support renewed blood cell
production after abrogating the autoimmune response.
The possibility that we have reached a ceiling in the
percentage of patients with the capacity to respond
to immunosuppression was raised. Consistent with
this idea, the EBMT group reported that although
significant improvements in survival after IST occurred
over each decade between the 1970s and the 1990s,
unfortunately, survival of patients treated between 2000
and 2007 has remained unchanged compared to those
treated between 1990 and 2000 (Figure 3) [36].Figure 3. Survival among patients with severe aplastic anemia treated
with ATG-based immunosuppression reported to the EBMT database
(n 5 2400) [36].In the context of this lack of improvement in re-
sponse to IST, what agents or approaches might im-
prove survival or patient quality of life in the future?
A randomized study of 120 patients in the United
States comparing horse ATG with rabbit ATG
(NCT00260689) has completed accrual and will
soon offer insights into the quality and length of
response with these 2 agents. A few pilot studies
show responses to alemtuzumab, although this highly
immunosuppressive agent requires attentive support-
ive care measures to avoid life-threatening infectious
complications [37]. Other new immunosuppressive
agents will be tested in patients with relapse of SAA
to establish efficacy and toxicity. Finally, investigators
at Johns Hopkins University using high-dose cyclo-
phosphamide (Cy) without stem cell rescue have dem-
onstrated a high response rate with relatively low
toxicity in newly diagnosed patients [38]. The use of
high-dose Cy by other groups was associated with
high rates of early and late toxicities, leading to closure
of randomized trials examining this approach [39].
There is recent renewed interest in this agent as inves-
tigators in China have shown high rates of response
with manageable toxicity using lower doses of Cy
than used by the Hopkins group [40].Improvements in BMTOutcomes: A Case
for Earlier Intervention?
Survival after HLA-matched sibling BMT in pa-
tients with SAA less than 30 years old has exceeded
80% for the past 20 years, making this the preferred
approach for these patients. In the last decade, survival
of older BMT recipients improved significantly. Sev-
eral factors likely contributed to this improvement.
An EBMT analysis of HLA-matched sibling BMT
outcomes in patients older than 30 years showed a sta-
tistically significant improvement in survival when
a fludarabine (Flu)/Cy/ATG preparative regimen was
used, compared with traditional Cy/ATG approaches.
Five-year survival in the Flu/Cy/ATG cohort was
77%, compared to 60% in the Cy/ATG group, and pa-
tients between the ages of 30 and 40 years had a survival
probability exceeding 80% [41].
Survival after URD BMT also improved dramati-
cally in recent years (from 30%-40% in the 1990s
[42] to 70%-80% currently [11]). EBMT data using
Flu/Cy/ATG 6 low-dose total-body irradiation
(TBI) showed that improvement was especially notable
after 2004, and that patients have the best chance of sur-
vival after BMT when they undergo the procedure
within 2 years of diagnosis (Figure 4). Unpublished
data from the CIBMTR using similar approaches
show that 2-year survival rates after 8/8 HLA-
matched (using high-resolution typing) URD BMT
for SAA exceeds 80% (personal communication, M.
Eapen, CIBMTR). There are many possible reasons
Figure 4. Outcomes of URD BMT for SAA using fludarabine/cyclo-
phosphamide/ATG 6 low dose TBI reported to the EBMT. (A) Survival
after Flu/Cy/ATG with TBI (median age 27 (7-53 years) versus Flu/Cy/
ATG (median age 13 [3-51 years]). (B) Survival of patients transplanted
#2 years from diagnosis versus those receiving transplantation later in
their disease course. (C) Survival of patients transplanted in the most re-
cent era (after 2004 versus those transplanted earlier) [11].
Biol Blood Marrow Transplant 17:291-299, 2011 295Therapy for SAAfor these improvements: the advent of molecular HLA
typing resulting in better HLAmatching, modern sup-
portive care, and optimization of reduced-intensity
conditioning (RIC) approaches [12]. Patient selection
is also a factor. In early studies, BMT was only offered
to high-risk patients who had failed multiple rounds ofIST. There is now a tendency to offer BMT earlier in
the course of therapy [11,12]. Patients undergoing
transplantation earlier in their disease course are
more likely to begin the procedure with a history of
fewer infections and with a lower likelihood of iron
overload, renal dysfunction from long-term CsA,
transfusion-induced alloimmunization (which can in-
crease risk of rejection), or platelet refractoriness.
The major focus of recent clinical trials in URD
BMT for SAA has been optimizing preparative regi-
mens to allow sustained engraftment while minimizing
regimen-related toxicity. A study published by Deeg
et al. [12] evaluated de-escalation of TBI doses and
demonstrated better survival in patients receiving Cy
(200 mg/kg)/ATG plus 200 cGy TBI compared to
higher TBI doses. Five-year survival probabilities after
HLA-matchedURDBMTusing the regimen contain-
ing 200 cGy of TBI were 78% for patients 20 years of
age or younger and 50% for older patients. A second
optimization trial is currently underway under the aus-
pices of the BMT CTN. This trial (BMT CTN 0301;
NCT00326417) is designed to determine the optimal
dose of cyclophosphamide (0, 50, 100, 150 mg/kg)
when given in combinationwith Flu, ATG, and a single
dose of TBI (200 cGy). The 0- and 150-mg levels have
been closed because of rejection and toxicity, respec-
tively. The trial continues to accrue patients at the
50- and 100-mg dose levels. Thus, this type of condi-
tioning regimen should be considered investigational,
and caution should be exercised when selecting the
cyclophosphamide dose in this setting.
There is some concern about TBI-based regimens
increasing the risk ofmalignancies afterURDBMTfor
SAA. Studies demonstrating an increased risk of second
malignancies after related donor BMTwithTBI-based
regimens were published in the early 1990s. Those
studies involved patients treated in the 1970-1980s us-
ingTBI doses.900 cGy or total abdominal irradiation
(TAI) doses of 5-600 cGy [43,44]. Whether current
approaches using a single dose of 200 cGy of TBI
increase the risk of posttransplant malignancies is
unknown. Long-term follow-up of these patients is
very important.
The dramatic improvement in survival rates after
URD BMT that has occurred over the past decade
has raised an important question. In the context of cur-
rent therapy, when should patients with SAA be of-
fered URD transplantation? Although many groups
now support offering this approach after failure of first
IST, when should it be offered after subsequent fail-
ures? Can biologic risk factors for failure of IST help
determine the timing of URD BMT? What level of
HLA typing and matching is required? When can al-
ternative graft sources (cord blood, haploidentical do-
nors) be used? What is the quality of life of survivors
after URD or alternative donor transplantation?
Some insight into URD transplantation of younger
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was provided by Kosaka et al. [14]. In this study, 201
pediatric patients with SAA lacking HLA-matched
sibling donors were treated initially with IST. Of 60
patients who failed to respond at 6 months, 31 under-
went URD BMT if they had matched URDs (25 pa-
tients), single antigen–mismatched related donors (4
patients), or single antigen–mismatched cord blood
units (2 patients). Patients who did not have donors re-
ceived subsequent rounds of IST. Although overall
survival (OS) at 5 years was not different between the
transplantation and IST groups, failure-free survival
was dramatically better in the BMT group at 84% ver-
sus 9% (P5 .001), and the majority of patients treated
with subsequent courses of IST had continuing mar-
row failure.
An additional issue is the availability of suitable
HLA-matched donors. Only about 70% of Caucasian
patients will find a fully matched and available URD;
patients from ethnic groups such as Hispanic, Black,
or Asian-Pacific islander will find a fully matched and
available donor less than half of the time [45]. Cord
blood transplantation, which allows greater degrees
of donor-recipient HLA-match, might be considered
for patients without a suitable adult donor, but pub-
lished experience from Japan and unpublished
CIBMTR and European Group for Blood and Mar-
row Transplantation (EBMT) data show high rates
of rejection and survival rates of less than 50% after
cord blood transplantation for SAA [46]. Some small
studies using combinations of Flu/Cy/ATG/TBI for
conditioning show more promising survival rates after
cord blood transplantation [47], but larger validation
studies are required. Some groups have explored the
feasibility of haploidentical transplants, but reports
to date are anecdotal [48]. Novel approaches that im-
prove survival with the use of cord blood or haploi-
dentical donors are needed to allow all patients who
do not have good options with IST to undergo trans-
plantation.Should Age Determine the Choice of
Immunosuppression versus BMT?
Age is a significant factor in both IST and BMT
outcomes, with higher chances of failure and mortal-
ity, especially in patients.40 years of age. An analysis
published in 1999 showed that the response rates to
ATG/CsA IST among patients aged .60, 50-59, and
\50 years were 37%, 49%, and 57%, respectively; cor-
responding 5-year survival rates were 50%, 57%, and
72% [49]. In the decade since this analysis was pub-
lished, response rates to IST have not changed sub-
stantially, but there has been a steady improvement
in supportive care leading to increased survival after
both IST and BMT. Rates of GVHD are higher in
older patients, however, and remain a major barrierto successful outcomes.Whether URDBMT can offer
a survival advantage over IST in older patients is un-
clear; however, older patients failing IST may benefit
from BMT approaches aimed at reducing GVHD
while maintaining donor engraftment.Longitudinal and Long-Term Outcomes: Vital
Questions and Proposed Approaches
There are several barriers to advancing care of pa-
tients with SAA. First, the disease is rare. Only about
600 new cases/year are expected in the United States.
This makes all types of studies difficult because any
given center will only have a handful of patients. Sec-
ond, the natural history of the disease plays out over
more than a decade, with some patients failing multi-
ple courses of therapy, but still surviving for 5 to 10
years, and others developing late-onset secondary
MDS/AML. Third, referral to centers with specific ex-
pertise in SAA is sporadic and varies by patient loca-
tion. Referral is important to have the latest testing
performed to rule out inherited bone marrow failure
syndromes, hypoplastic MDS, and other conditions
that mimic SAA, and to enroll patients in studies.
Fourth, timing and indications for referral for trans-
plant vary considerably among centers, with many pa-
tients delayed excessively and referred to BMT only
after they have developed active infections, significant
transfusion burden, alloimmunization, and/or platelet
refractoriness. Finally, because patients with SAA may
be seen by local physicians or hematologists, referred
to a regional academic center, and then referred a sec-
ond time for BMT evaluation, it is difficult to follow
patients from diagnosis through all of their therapeutic
courses with an observation period sufficient to under-
stand their long-term outcomes. In the United States,
particularly, a mechanism to track patients through
multiple care providers is lacking.
The SAA working group agreed that advances in
biology and BMT survival warrant a series of initia-
tives to better understand the appropriate roles and
timing of IST and BMT in treating SAA. One impor-
tant effort that would greatly assist in moving the field
forward would be to create a mechanism for identify-
ing a high percentage of SAA patients at diagnosis,
obtaining blood specimens to evaluate prognostic bio-
markers, and following these patients through their
treatment courses. Biologic samples for later studies
could be obtained, with appropriate consent, and an
SAA repository established. Patients could be offered
participation in studies of related donor BMT, IST,
URD BMT, and alternative donor BMT as they be-
came eligible for such studies. BMT timing would be
determined by patient age, the availability of well-
matched related or unrelated donors, response to IST,
and risk as determined by biologic markers. All patients
would be followed long term, and quality-of-life studies
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tients receiving URD BMT versus IST.
The working group felt that the most appropriate
way to improve care and enroll patients into a large
registry study would be to designate regional centers
of excellence, where comprehensive evaluations, in-
cluding key biologic assessments (telomere studies,
etc.), could be performed at diagnosis and other key
time points. Vital to this process is early assurance
that the diagnosis of SAA is correct. A subcommittee
headed by Dr. Richard Harris was appointed to assem-
ble comprehensive diagnostic guidelines including
tests to rule out inherited BM failure syndromes and
other non-SAA diseases. Because the therapy of SAA
patients sometimes involves transplantation, and the
CIBMTR currently has a large database of informa-
tion on patients receiving BMT, theCIBMTR is a pos-
sible choice to manage an SAA registry or longitudinal
observational study. Trials of biology, IST, and BMT
could be facilitated by a population-based SAA out-
comes registry by identifying potential study subjects;
patients would benefit by having wider access to stud-
ies of relevance to them. Patients in the registry could
also be targeted for distribution of educational and
support materials. The working group plans to seek
funding from patient advocacy groups, private corpo-
rations, and governmental funding sources to estab-
lished a population-based outcomes registry and
accompanying biologic sample repository to facilitate
studies to address many of the issues discussed in this
document.
The important questions in the therapy of acquired
SAA can be addressed most effectively with collabora-
tion among transplantation physicians, hematologists
interested in IST, and scientists studying the biology
of marrow failure. The relevant issues are interdepen-
dent. For instance, can telomere length and telomerase
complex mutations help predict whether patients will
fail IST and should, therefore, seek early transplanta-
tion therapy? Can selected biological factors (cytokine
profiles, etc.) better define clinical risk groups? If we
can define patients at high risk of IST failure, do the
same or different factors predict outcomes after
BMT? If a patient either fails to respond to IST or
relapses afterward, can new agents induce or prolong
responses (alemtuzumab, etc.)? Can cyclophospha-
mide, given at a modified dose, improve the durability
of initial responses without excessive early morbidity?
Finally, we need to know whether novel strategies for
URD BMT that decrease GVHD and maintain en-
graftment can be developed and performed safely
with reasonable survival in older patients. Can alterna-
tive donor grafts be used successfully so that more
patients are able to go to transplantation if immuno-
suppression is unsuccessful?
These questions can be directly addressed through
the proposed SAA registry/biology study, because atgiven time points (first or subsequent failure of IST,
etc.), patients who have appropriate donors and go to
BMT can be compared with similar patients who
undergo IST. Questions regarding access to BMT (in-
ability to get BMT because of insurance, etc.) can be
addressed by the registry study as well. Transplanta-
tion studies could be performed through the BMT
CTN in cooperation with international study groups
as needed to allow for sufficient accrual or to rapidly
test highly promising ideas.CONCLUSIONS
Treatment for SAA has advanced in the past de-
cade, most notably with (1) the development of biolog-
ical measures that may allow clinical risk classification,
and (2) improvement in survival after HLA-matched
URD BMT. Creation of an SAA outcomes registry
and specimen repository would allow investigators to
follow patients from diagnosis through all of their
therapies, would facilitate better studies comparing
specific therapies, and thus may help optimize timing
of URD BMT for patients failing IST. Cooperation
among hematologists, transplant physicians, and basic
scientists in the study and treatment of SAA patients
should speed advances in clinical care and improve
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